BI takes interferon-free Hep C combo into Phase III
This article was originally published in Scrip
Boehringer Ingelheim has begun a pivotal Phase III study of its interferon-free triple combination regimen for hepatitis C, containing its investigational products, the protease inhibitor faldaprevir (BI 201335), and its non-nucleoside polymerase inhibitor BI 207127, together with ribavirin.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.